Asia Pacific Cancer Vaccines Market
Published On: Oct 2020
Published On: Oct 2020
Cancer Vaccines Market for Dendritic Cells Cancer Vaccines Segment to Grow at Fastest CAGR during Forecast Period
According to our new market research study on “Cancer Vaccines Market to 2027 – Asia Pacific Analysis and Forecast – by Technology, Type, Indication, and End Use,” the market is expected to reach US$ 3,131.09 million in 2027 from US$ 861.55 million in 2019; it is estimated to grow at a CAGR of 17.9% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific Cancer Vaccines Market and the drivers and restraints pertaining to the market growth.
Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines. The in recombinant cancer vaccines segment held the largest share of the market in 2019. Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.
The Asia Pacific Cancer Vaccines market growth is mainly attributed to factors such as growing prevalence of cancer, and rising government initiatives to prevent it. However, the challenges in cancer vaccines industry like expensive cost restrains the growth of the market.
AstraZeneca, GlaxoSmithKline plc., Aduro Biotech Inc, Pfizer Inc., Sanofi, Bristol-Myers Squibb, Moderna, Inc., OncBioMune Pharmaceuticals Inc., MaxiVAX, Nouscom are among the leading companies operating in the Cancer Vaccines Market.
Asia Pacific Cancer Vaccines market, By Country, 2019(%share)
The report segments Asia Pacific Cancer Vaccines market as follows:
By Technology
By Type
By Indication
By End-Use
By Country
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
